Haleon PLC Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/9/2026)
| Balance Sheet | Total Assets | 32,630,000,000.00 | ROE | 50.34 % |
| Balance Sheet | Total Equity | 16,425,000,000.00 | ROA | 5.11 % |
| Cashflow | Capital Expenditures | -322,000,000.00 | P/FCF | 16.19 |
| Cashflow | Free Cash Flow | 2,015,000,064.00 | – | – |
| Cashflow | Operating Cash Flow | 2,337,000,000.00 | P/CF | 13.96 |
| Income | Earnings per Share (diluted) | 0.19 | Div. Yield | 1.93 % |
| Income | Net Income | 1,667,000,000.00 | P/E | 19.06 |
| Income | Shares Outstanding | 9,010,810,000.00 | P/B | 1.99 |
| Income | Total Revenue | 11,030,000,000.00 | P/S | 2.96 |
Ratios calculated on: 10/14/2026
Company Description
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.haleon.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more